Group 1 - The core viewpoint of the news is that Han's Biotech Company has successfully completed its IPO process, raising significant interest from investors with a substantial oversubscription rate of 2511 times [1] - Han's Biotech plans to issue 18.32 million H-shares, with a public offering accounting for 10% of the total shares, and the share price is set between HKD 28 to 32 [1] - The company has secured cornerstone investments totaling HKD 93.37 million from seven investors, representing 15.93% of the global offering [1] Group 2 - Since 2016, Han's Biotech has developed a product pipeline that includes one core product and nine other candidates, focusing on oncology and autoimmune markets [2] - The core product, HX009, is a bispecific antibody fusion protein targeting CD47 and PD-1, which is reported to be leading in clinical trial progress among similar products [2] - Financially, Han's Biotech has recorded operating losses with no profits during the reporting period, with losses of RMB 85.16 million, RMB 117 million, and RMB 87.44 million for the fiscal years ending August 31, 2023, 2024, and 2025 respectively [2] Group 3 - The company plans to allocate approximately 35% of the net proceeds from the global offering to the research and development of its core product HX009, 33% to its major products HX301 and HX044, and 17% to other important products [3] - Additionally, about 5% of the proceeds will be used for commercialization and business development activities, while 10% will be allocated for working capital and other general corporate purposes [3]
翰思艾泰-B招股结束 孖展认购额录得1472.9亿港元 超购2511倍